INTRODUCTION

Perinatal asphyxia is an important cause of neonatal mortality and permanent neurologic sequelae such as cerebral palsy, mental retardation, learning disability, and epilepsy in survivors (1-3). As most asphyxial events occur before birth, it is practically impossible to institute some neuroprotective treatments during the primary hypoxic-ischemic insult. However, it has become clear that although cerebral hypoxia-ischemia may cause immediate cell death during the insult, it can also lead to delayed cerebral injury hours, days or even weeks later (4-6). Thus the brain damage occurring during reoxygenation-reperfusion could give us a therapeutic window during which we may be able to intervene before delayed irreversible cell death occurs, and thus to inhibit or reverse permanent neonatal brain damage (3, 5, 7-9).

There are two major forms of cell death that can be distinguished during hypoxic-ischemic brain injury (10-13). Necrosis is a rapid passive form of cell death characterized by prominent acute cell body swelling with subsequent cell lysis. Apoptosis is a delayed active form of cell death characterized by compaction of the cell body and internucleosomal DNA cleavage, and requiring new protein synthesis (14). In an adult rodent model of middle cerebral artery occlusion (MCAO) with cycloheximide treatment, the therapeutic window, of up to 6 hr, existed only in the apoptotic cell death following mild ischemia, but not in the acute necrosis following severe ischemia (15). In the developing brain, apoptosis has been found to play an important role in mediating neurodegeneration in pathological conditions (4, 5, 9, 12, 16). Furthermore, newborn brain infarction developed and progressed in a much delayed fashion (17, 18); apoptotic cells were still observed at the peri-infarct area even weeks after the hypoxic-ischemic insult (18). Therefore, these findings raise the intriguing possibility that a delayed anti-apoptotic therapeutic intervention might prove to be valuable in reducing neonatal hypoxic-ischemic brain injury.

We have previously shown that cycloheximide significantly inhibited apoptosis, and reduced ensuing cerebral infarction in a newborn rat model of cerebral hypoxia-ischemia. This study was performed to determine the therapeutic window for cycloheximide therapy. Seven day-old newborn rat pups were subjected to 100 min of 8% oxygen following a unilateral carotid artery ligation, and cycloheximide was given at 0, 6, 12 and 24 hr after hypoxia-ischemia (HI). Apoptosis or necrosis was identified by performing flow cytometry with a combination of fluorescinated annexin V and propidium iodide, and the extent of cerebral infarction was evaluated with triphenyl tetrazolium chloride (TTC) at 48 hr and 72 hr after HI, respectively. With cycloheximide treatment at 0 hr after HI, both apoptotic and necrotic cells by flow cytometry were significantly reduced, only necrotic cells were significantly reduced at 6 and 12 hr, and no protective effect was seen if administration was delayed until 24 hr after HI compared to the HI control group. Infarct volume, measured by TTC, was significantly reduced by 92% and 61% when cycloheximide was given at 0 or 6 hr after HI respectively; however, there was an insignificant trend in infarct reduction if cycloheximide was administered 12 hr after HI, and no protective effect was observed when administration was delayed until 24 hr after HI. In summary, cycloheximide was neuroprotective when given within 6 hr after HI in the developing newborn rat brain.

Key Words: Hypoxia-Ischemia, Brain; Animals, Newborn; Apoptosis; Cycloheximide

Therapeutic Window for Cycloheximide Treatment after Hypoxic-Ischemic Brain Injury in Neonatal Rats

We have previously shown that cycloheximide significantly inhibited apoptosis, and reduced ensuing cerebral infarction in a newborn rat model of cerebral hypoxia-ischemia. This study was performed to determine the therapeutic window for cycloheximide therapy. Seven day-old newborn rat pups were subjected to 100 min of 8% oxygen following a unilateral carotid artery ligation, and cycloheximide was given at 0, 6, 12 and 24 hr after hypoxia-ischemia (HI). Apoptosis or necrosis was identified by performing flow cytometry with a combination of fluorescinated annexin V and propidium iodide, and the extent of cerebral infarction was evaluated with triphenyl tetrazolium chloride (TTC) at 48 hr and 72 hr after HI, respectively. With cycloheximide treatment at 0 hr after HI, both apoptotic and necrotic cells by flow cytometry were significantly reduced, only necrotic cells were significantly reduced at 6 and 12 hr, and no protective effect was seen if administration was delayed until 24 hr after HI compared to the HI control group. Infarct volume, measured by TTC, was significantly reduced by 92% and 61% when cycloheximide was given at 0 or 6 hr after HI respectively; however, there was an insignificant trend in infarct reduction if cycloheximide was administered 12 hr after HI, and no protective effect was observed when administration was delayed until 24 hr after HI. In summary, cycloheximide was neuroprotective when given within 6 hr after HI in the developing newborn rat brain.

Key Words: Hypoxia-Ischemia, Brain; Animals, Newborn; Apoptosis; Cycloheximide

Won Soon Park, Dong Kyung Sung*, Saem Kang*, Soo Hyun Koo, Yu Jin Kim, Jang Hoon Lee, Yun Sil Chang, Munhyang Lee

Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Samsung Biomedical Research Institute*, Seoul, Korea

Address for correspondence
Munhyang Lee, M.D.
Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Iwon-dong, Gangnam-gu, Seoul 135-710, Korea
Tel: +82 2-3410-3522, Fax: +82 2-3410-0043
E-mail: mhlee@smc.samsung.co.kr

*This study was supported by intramural grant of the Samsung Biomedical Research Institute (C-A4-108-1).
enrollment of newborns for clinical trials can take several hours for a mother to recover from a delivery and to give informed consent, and it is practically impossible to start any therapy immediately after birth. As there is a danger that delay in applying potentially brain-saving treatments beyond the therapeutic window might abolish or drastically reduce its therapeutic effectiveness (3, 7, 8, 19), better understanding of the therapeutic window must be obtained before translation of experimental results to clinical trials. The present study was thus performed to determine the therapeutic window for cycloheximide treatment on neonatal hypoxic-ischemic brain injury.

MATERIALS AND METHODS

Hypoxia-ischemia

The experimental protocols described herein were reviewed and approved by the animal care and use committee of the Samsung Biomedical Research Institute, Seoul, Korea. This study also followed the institutional and National Institute of Health guidelines for laboratory animal care.

Unilateral carotid artery ligation was performed in 7-day old Sprague Dawley rat pups (Daihan Biolink Co., Seoul, Korea) under methoxyflurane anesthesia. The neck was incised in the midline, and the right common carotid artery was permanently ligated with 4-0 silk. Total time of surgery in each animal never exceeded 5 min. Following surgery, rats were returned to their mother for recovery and feeding for 2 hr. The pups were then exposed to a 100 min-period of hypoxia (8% O₂, 92% N₂) by placing them in an airtight chamber partially submerged in a temperature controlled water bath to maintain the ambient temperature inside the chamber at a constant 36°C. In the HI with cycloheximide treatment group, the rat pups received an intraperitoneal injection of cycloheximide at a dose of 0.6 mg/kg (20) at 0, 6, 12 or 24 hr of recovery, and an equal volume of normal saline was given to a HI control group. Then, the rat pups were returned to their dam until sacrifice; the whole brain tissue was sampled from the brain for histopathological and morphometric analysis. Tissue sections were obtained at a mid-portions of the ipsilateral cerebral cortex and stained with 2% TTC (Sigma, St. Louis, MO, U.S.A.) at 48 and 72 hr after HI, respectively. Morphometric analysis of infarct volume

Infarct volumes were measured by morphometric analysis of infarct areas that were defined by TTC (Sigma, St. Louis, MO, U.S.A.) at 72 hr after HI (15). This method provides an overall measure of cell injury presented by depleted NA-DPH and hence the inability to reduce TTC to its colored form. After intracardiac perfusion with 20 mL of 0.9% NaCl, brains were cooled in ice-cold saline for 5 min, and then sliced into 1 mm thick coronal sections using rat brain matrices (Harvard Bioscience, South Natick, MA, U.S.A.). The brain slices were incubated in phosphate-buffered saline (pH 7.4) containing 2% TTC at 37°C for 20 min, and then stored in 10% neutral-buffered formalin. A cross-sectional area of the TTC-stained region for each brain slice was determined using an Optimas 6.51 Image Analysis System (Media Cybernetics Inc., Silver Spring, MD, U.S.A.). After integration of these stained areas, the indirect method of Swanson was used to determine infarct volume (subtraction of residual right hemisphere cortical volume from the cortical volume of the intact hemisphere) (22).

Statistical analysis

All data are expressed as mean ± standard deviation. Data were analyzed by one-way ANOVA or Kruskal-Wallis test for inter-group comparisons. A p-value of <0.05 was considered significant.

RESULTS

Flow cytometry

Representative analysis and regional percentage of an annexin V versus PI dot plot of ipsilateral cerebral cortex in HI control and HI with cycloheximide-treated groups (0, 6, 12, 24 hr after HI, respectively) at 48 hr after HI are presented in Fig. 1. When cycloheximide was given immediately after hypoxia-ischemia (0 hr), the percentage of damaged, necrotic and apoptotic cells in the respective area of Q1 (annexin V+/PI+), Q2 (annexin V+/PI+ and annexin V+/PI-), and the live cells in Q3 (annexin V-/PI-) increased significantly compared to the HI control group. When cycloheximide was administered 6 hr after HI, the damaged and necrotic cells in Q1 and Q2 were significantly decreased, and the decrease of apoptotic cells in Q4 did not reach a statistical significance compared to the HI control group. With cycloheximide treatment at 12 hr after HI, only the necrotic cells
in Q2 were significantly reduced compared to the HI control group, and no protective effect was seen if administration was delayed until 24 hr after HI.

Morphometric analysis of infarct volume

Infarct volume, as measured by morphometric analysis of infarct areas with TTC, was significantly reduced by 92% and 61% when cycloheximide was given 0 or 6 hr after HI respectively, but showed an insignificant trend in infarct reduction if cycloheximide was administered 12 hr after HI compared to the HI control group, and no protective effect was observed when administration was delayed until 24 hr after HI (Fig. 2).

In both flow cytometric analyses and infarct volume measurements, there was a trend of better neuroprotection with the earlier administration of cycloheximide after HI.

DISCUSSION

In the present study, cycloheximide significantly attenuated the brain injury due to HI when given up to 6 hr after HI in a newborn rat pup model. These findings support the assumption that a therapeutic window exists in the early hours following a primary hypoxic-ischemic insult when intervention can attenuate irreversible brain damage in newborn infants with perinatal asphyxia (3, 5, 7-9). As the delay in administering a drug in humans beyond the therapeutic window might obscure or nullify its therapeutic effectiveness, time is a critical element for successful clinical trials (3, 7, 8, 19). Furthermore, a trend of better neuroprotection with the earlier administration of cycloheximide after HI was observed in the present study. These findings suggest
that an early selection of patients and administration of the treatment as soon as possible is of utmost importance for maximal neuroprotection in clinical trials (3, 8).

In an adult rat model of MCAO (15), cycloheximide reduced infarct volume when given up to 6 hr after 30 min of mild transient ischemia. However, if the duration of ischemic insult was increased to 90 min, the therapeutic window for delayed cycloheximide was only 30 min, and even pretreatment of cycloheximide was ineffective in permanent MCAO. These findings further support a therapeutic window for cycloheximide treatment exists only in the apoptotic delayed form of cell death, but not for acute necrosis. The same therapeutic window of up to 6 hr with cycloheximide treatment observed both in the newborn rat pup model of the present study and in the adult model of MCAO (15), also suggests that the mode of neuronal death, apoptosis or necrosis, rather than the maturity of the brain itself are the important factors for this therapeutic window.

Further study will be necessary to elucidate the mechanisms underlying the cycloheximide-induced neuroprotective effects observed here. The reason why inhibition of protein synthesis should block apoptosis has not been completely understood, but presumably some critical protein must be synthesized de novo before apoptosis can proceed (14). However, actions of cycloheximide relevant to apoptosis other than the inhibition of death protein synthesis have also been recognized. Furukawa et al. (23) showed that cycloheximide treatment at low levels insufficient to fully inhibit protein synthesis enhances Bcl-2 expression. Cycloheximide can also attenuate free radical stress by inhibiting prostaglandin synthesis (24), and by increasing the availability of cysteine for glutathione synthesis (25).

In our previous (18) and present studies, significant reduction of both apoptotic and necrotic cells, measured by flow cytometry and brain infarction, was observed with cycloheximide treatment. As a working hypothesis, we think it is likely that inhibition of apoptosis with cycloheximide might also attenuate the secondary necrotic cells representing the secondary degradation of apoptotic cells (12, 26), and the ensuing tissue necrosis (cerebral infarction). Administration of cycloheximide within the therapeutic window could attenuate activation of the neurotoxic, probably apoptotic, cascade ultimately leading to delayed cell death and irreversible brain damage hours, days or months later (3, 5, 7-9, 15). Apoptotic neuronal death is a relatively slow and multi-step process, and the entire process, from the initial trigger to the destruction of the cell, can take hours or even days (4-6, 27). However, our data demonstrating a therapeutic window less than 6 hr after HI to inhibit or reverse apoptosis with cycloheximide suggests that although the whole apoptotic process may be gradual and delayed, the fate of cells would be determined early after the insult, and once the apoptotic events proceed beyond the critical control point, the cell may become irreversibly committed to death (27, 28).

In conclusion, cycloheximide treatment was effective in attenuating brain injury within a 6 hr therapeutic window after HI in a newborn rat pup model. Our data support the possibility that protein synthesis inhibitors, as well as other anti-apoptotic strategies, may have therapeutic utility in hypoxic-ischemic events of the developing newborn brain even when treatment is delayed for up to 6 hr after the primary asphyxial insult.

REFERENCES

1. Delivoria-Papadopoulos M, Mishra OP. Mechanisms of cerebral injury in perinatal asphyxia and strategies for prevention. J Pediatr 1998; 132: S30-4.
2. Vannucci RC, Perlman JM. Interventions for perinatal hypoxic-ischemic encephalopathy. Pediatrics 1997; 100: 1004-14.
3. Robertson NJ, Edwards AD. Recent advances in developing neuroprotective strategies for perinatal asphyxia. Curr Opin Pediatr 1998; 10: 575-80.
4. Chang YS, Park WS, Lee M, Kim KS, Shin SM, Choi JH. Near-infrared spectroscopic monitoring of secondary cerebral energy failure after transient global hypoxia-ischemia in the newborn piglet. Neurol Res 1998; 21: 216-24.
5. Cheng Y, Deshmukh M, D’Costa A, Demaro JA, Gidday JM, Shah A, Sun Y, Jacun MF, Johnson EM, Holtzman DM. Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury. J Clin Invest 1998; 101: 1992-9.
6. Kirino T. Delayed neuronal death in the gerbil hippocampus following ischemia. Brain Res 1997; 239: 57-69.
7. Whitelaw A, Thorensen M. Clinical trials after perinatal asphyxia. Curr Opin Pediatr 2002; 14: 664-8.
8. Groenendaal F, de Vries LS. Selection of babies for intervention after birth asphyxia. Semin Neonatol 2000; 5: 17-32.
9. Fellman V, Raivio KO. Reperfusion injury as the mechanism of brain damage after perinatal asphyxia. Pediatr Res 1997; 41: 599-606.
10. Lindek MD, Zobrist RH, Hatfield MD. Evidence supporting a role for programmed cell death in focal cerebral ischemia in rats. Stroke 1993; 24: 2002-9.
11. Renovoize C, Biola A, Pallardy M, Beaud J. Apoptosis: identification of dying cells. Cell Biol Toxicol 1998; 14: 111-20.
12. Taylor DL, Edwards AD, Mehmet H. Oxidative metabolism, apoptosis and perinatal brain injury. Brain Pathol 1999; 9: 93-117.
13. Martin LJ, Al-Abdulla NA, Branbrink AM, Kirsch JR, Siever FE, Portera-Cailliau C. Neurodegeneration in excitotoxicity, global cerebral ischemia, and target deprivation: a perspective on the contributions of apoptosis and necrosis. Brain Res Bull 1998; 46: 281-309.
14. Johnson EM Jr, Deckwerth TL. Molecular mechanisms of developmental neuronal death. Annu Rev Neurosci 1993; 16: 31-46.
15. Snider BJ, Du C, Wei L, Choi DW. Cycloheximide reduces infarct volume when administered up to 6 h after mild focal ischemia in rats. Brain Res 2001; 917: 147-57.
H. Blomgren K. The influence of age on apoptotic and other mechanisms of cell death after cerebral hypoxia-ischemia. Cell Death Differ 2005; 12: 162-76.

17. Geddes R, Vannucci RC, Vannucci SJ. Delayed cerebral atrophy following moderate hypoxia-ischemia in the immature rat. Dev Neurosci 2001; 23: 180-5.

18. Park WS, Sung DK, Kang S, Koo SH, Kim YJ, Lee JH, Chang YS, Lee M. Neuroprotective effect of cycloheximide on hypoxic-ischemic brain injury in neonatal rats. J Korean Med Sci 2006; 21: 337-41.

19. Kidwell CS, Liebeskind DS, Starkman S, Saver JL. Trends in acute ischemic stroke trials through the 20th century. Stroke 2001; 32: 1349-59.

20. Pavlik A, Teisinger J. Effect of cycloheximide administered to rats in early postnatal life: prolonged of DNA synthesis in the developing brain. Brain Res 1980; 192: 531-41.

21. Hwang JH, Sung DK, Choi CW, Kang S, Chang YS, Park WS, Lee M. Single cell dissociation methods for flow cytometric analysis of hypoxia-ischemia injured newborn rat pup brain. Korean J Pediatr 2005; 48: 545-50.

22. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR. A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab 1990; 10: 290-3.

23. Furukawa K, Estus S, Fu W, Mark RJ, Mattson MP. Neuroprotective action of cycloheximide involves induction of Bcl-2 and antioxidant pathways. J Cell Biol 1997; 136: 1137-49.

24. Nam MJ, Thore C, Busija D. Rapid induction of prostaglandin synthesis in piglet astroglial cells by interleukin 1a. Brain Res Bull 1995; 36: 215-8.

25. Ratan RR, Murphy TH, Baraban JM. Macromolecular synthesis inhibitors prevent oxidative stress-induced apoptosis in embryonic cortical neurons by shunting cysteine from protein synthesis to glutathione. J Neurosci 1994; 14: 4385-92.

26. Honda O, Kuroda M, Joja I, Asaumi J, Takeda Y, Akaki S, Togami I, Kanazawa S, Kawasaki S, Hiraki Y. Assessment of secondary necrosis of Jurkat cells using a new microscopic system and double staining method with annexin V and propidium iodide. Int J Oncol 2000; 16: 283-8.

27. Green DR. Apoptotic pathways: ten minutes to dead. Cell 2005; 121: 671-4.

28. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116: 205-19.